Anti-amyloid antibodies
Lecanemab, donanemab and related antibodies for early Alzheimer's disease.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 9, 4, 7, 14, 12.
All papers from the last 12 months
405 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 TrialNeurol Clin Pract2026 DecPMID 42854182
- Effective amyloid clearance with lecanemab in a female with Alzheimer's disease: A case reportRadiol Case Rep2026 DecPMID 42750750
- Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling studyJ Med Econ2026 DecPMID 41603883
- Predictors of Antiamyloid Medication Utilization and Adherence Among People With Alzheimer Disease and Mild Cognitive ImpairmentNeurology2026 Nov 10PMID 42879726
- The use of blood biomarkers to understand responses to lecanemab treatmentLancet Neurol2026 NovPMID 42785334
- Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort studyLancet Neurol2026 NovPMID 42785333
- Corrigendum to "Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181" [The Journal of Prevention of Alzheimer's Disease (2026) 100664]J Prev Alzheimers Dis2026 NovPMID 42743693
- Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181J Prev Alzheimers Dis2026 NovPMID 42664573
- The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapyJ Prev Alzheimers Dis2026 NovPMID 42594414
- Analysis of the dual role of amyloid-beta in Alzheimer's disease through multi-omics integrationNeural Regen Res2026 Nov 1PMID 41622475
More neurology trends
All specialties →CGRP-targeted migraine treatment
Gepants and anti-CGRP antibodies for migraine.
Tenecteplase in stroke
Tenecteplase as the thrombolytic for acute ischaemic stroke.
Key point: Intravenous tenecteplase before thrombectomy showed benefit in ASPECTS <8, but no functional improvement and possible safety concerns in ASPECTS 8-10.
Post-stroke dysphagia
Studies of swallowing disorders after stroke and their treatment, including neuromodulation.
New myasthenia gravis therapies
FcRn blockers and complement inhibitors in myasthenia gravis.
Key point: Terminal complement pathway inhibitors and neonatal Fc receptor antagonists are reshaping myasthenia gravis treatment, with robust evidence of efficacy and safety.
Wearable seizure detection
Wearable devices and algorithms to detect or forecast seizures.
Autoimmune encephalitis
Antibody-mediated encephalitis, its diagnosis and treatment.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
lecanemab[tiab] OR donanemab[tiab] OR aducanumab[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.